Celemics Inc., a privately held company based in Seoul, South Korea, develops and manufactures proprietary DNA and genetic sequencing test kits and panels. In addition to test kit manufacturing, Celemics also provides a full spectrum of Next Generation Sequencing and Bioinformatics services to university researchers, hospitals, care providers, and pharmaceutical organizations.
In October 2015 Celemics announced its expansion into the North American market with the establishment of Celemics America, Inc.
Celemics manufactures the Next Generation Sequencing test kit in Asia and Europe. Next Generation Sequencing, or NGS, facilitates both hereditary and somatic genetic testing.
Targeted Sequencing involves isolating genomic regions of interest from the whole genome and utilizes synthetic strands of DNA or RNA called probes, which assist in detecting the presence of a gene in a long DNA sequence. In order to address uniformity and coverage limitations associated with Targeted Sequencing, Celemics has developed and introduced a technology which incorporates rebalancing of probes following a pre-production pilot test.
